9.75
                                            Precedente Chiudi:
              $9.78
            Aprire:
              $9.72
            Volume 24 ore:
                57,296
            Relative Volume:
              0.52
            Capitalizzazione di mercato:
                $140.58M
            Reddito:
              $166.88M
            Utile/perdita netta:
              $-74.18M
            Rapporto P/E:
              -1.9231
            EPS:
                -5.07
            Flusso di cassa netto:
                $1.14M
            1 W Prestazione:
              -2.60%
            1M Prestazione:
              +3.72%
            6M Prestazione:
                -32.90%
            1 anno Prestazione:
              -43.02%
            Anika Therapeutics Inc Stock (ANIK) Company Profile
Nome
                  
                      Anika Therapeutics Inc
                    
                Settore
                  Telefono
                  
                      (781) 457-9000
                    
                Indirizzo
                  
                      32 WIGGINS AVENUE, BEDFORD, MA
                    
                Confronta ANIK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                ANIK
                            
                             Anika Therapeutics Inc | 9.75 | 141.01M | 166.88M | -74.18M | 1.14M | -5.07 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione | 
|---|---|---|---|
| 2025-04-17 | Iniziato | B. Riley Securities | Buy | 
| 2024-11-01 | Reiterato | Barrington Research | Outperform | 
| 2023-08-14 | Aggiornamento | Barrington Research | Mkt Perform → Outperform | 
| 2023-03-07 | Downgrade | Barrington Research | Outperform → Mkt Perform | 
| 2022-11-09 | Aggiornamento | Barrington Research | Mkt Perform → Outperform | 
| 2022-10-14 | Ripresa | Stephens | Equal-Weight | 
| 2022-03-09 | Downgrade | Barrington Research | Outperform → Mkt Perform | 
| 2022-03-09 | Downgrade | Stephens | Overweight → Equal-Weight | 
| 2021-11-16 | Iniziato | Stephens | Overweight | 
| 2021-07-16 | Iniziato | UBS | Neutral | 
| 2020-12-16 | Aggiornamento | Barrington Research | Mkt Perform → Outperform | 
| 2020-05-08 | Downgrade | Barrington Research | Outperform → Mkt Perform | 
| 2020-01-21 | Aggiornamento | Sidoti | Neutral → Buy | 
| 2020-01-10 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy | 
| 2019-11-05 | Iniziato | BWS Financial | Sell | 
| 2019-09-24 | Reiterato | Barrington Research | Outperform | 
| 2019-09-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform | 
| 2019-07-25 | Aggiornamento | First Analysis Sec | Neutral → Strong Buy | 
| 2019-02-22 | Downgrade | First Analysis Sec | Outperform → Neutral | 
| 2019-02-22 | Downgrade | Sidoti | Buy → Neutral | 
| 2018-07-27 | Aggiornamento | Barrington Research | Mkt Perform → Outperform | 
| 2018-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform | 
| 2018-06-20 | Downgrade | First Analysis Sec | Overweight → Equal-Weight | 
| 2018-05-04 | Aggiornamento | Barrington Research | Mkt Perform → Outperform | 
| 2018-02-23 | Downgrade | Barrington Research | Outperform → Mkt Perform | 
| 2018-01-24 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight | 
| 2017-10-27 | Reiterato | Barrington Research | Outperform | 
| 2016-05-09 | Aggiornamento | Singular Research | BUY - Long-Term → Buy | 
| 2016-04-27 | Downgrade | Northland Capital | Outperform → Market Perform | 
| 2016-02-26 | Reiterato | Barrington Research | Outperform | 
                    Mostra tutto
                     
                  
                Anika Therapeutics Inc Borsa (ANIK) Ultime notizie
Anika Therapeutics (NASDAQ:ANIK) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 20252025 EndofYear Setup & Technical Pattern Based Signals - newser.com
What dividend safety rating applies to Anika Therapeutics Inc. (AKP) stockTrade Ideas & Scalable Portfolio Growth Methods - newser.com
Key metrics from Anika Therapeutics Inc.’s quarterly data2025 Winners & Losers & Verified Technical Signals - newser.com
Is Anika Therapeutics Inc. stock supported by strong cash flows2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Why Anika Therapeutics Inc. stock could rally in 2025Weekly Profit Analysis & Breakout Confirmation Alerts - newser.com
Does Anika Therapeutics Inc. show high probability of reboundJuly 2025 EndofMonth & Safe Entry Trade Reports - newser.com
Why Anika Therapeutics Inc. stock could outperform in 2025Bear Alert & Low Risk High Win Rate Stock Picks - newser.com
Detecting support and resistance levels for Anika Therapeutics Inc.Inflation Watch & Long Hold Capital Preservation Plans - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthTrade Ideas & Risk Managed Investment Entry Signals - newser.com
Strategies to average down on Anika Therapeutics Inc.2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
How to escape a deep drawdown in Anika Therapeutics Inc.2025 Growth vs Value & Smart Allocation Stock Reports - newser.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a favorite amongst institutional investors who own 60% - Yahoo Finance
Using AI based signals to follow Anika Therapeutics Inc.Quarterly Investment Review & Stepwise Entry/Exit Trade Alerts - newser.com
Can Anika Therapeutics Inc. stock sustain revenue growth2025 Momentum Check & Real-Time Price Movement Reports - Fundação Cultural do Pará
Will Anika Therapeutics Inc. (AKP) stock benefit from sector leadershipMarket Performance Report & Daily Technical Forecast Reports - Fundação Cultural do Pará
Can Anika Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Macro Moves & Fast Gain Swing Alerts - Fundação Cultural do Pará
Is Anika Therapeutics Inc. stock attractive for growth ETFsWeekly Gains Summary & Long-Term Safe Investment Ideas - Fundação Cultural do Pará
Anika Therapeutics’ Integrity Implant System Study: A Market Game Changer? - TipRanks
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anika Therapeutics Inc Azioni (ANIK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale | 
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer | Mar 17 '25 | Option Exercise | 0.00 | 3,637 | 0 | 21,722 | 
| Colleran David | EVP, General Counsel, Corp Sec | Mar 17 '25 | Option Exercise | 0.00 | 6,448 | 0 | 49,847 | 
| Blanchard Cheryl R | President, CEO, Director | Mar 17 '25 | Option Exercise | 0.00 | 25,132 | 0 | 209,472 | 
| Nunes Anne | SVP, Chief Operations Officer | Mar 11 '25 | Option Exercise | 0.00 | 2,561 | 0 | 18,837 | 
| Colleran David | EVP, General Counsel, Corp Sec | Mar 11 '25 | Option Exercise | 0.00 | 7,663 | 0 | 45,649 | 
| Blanchard Cheryl R | President, CEO, Director | Mar 11 '25 | Option Exercise | 0.00 | 30,060 | 0 | 197,015 | 
| Nunes Anne | SVP, Chief Operations Officer | Mar 10 '25 | Option Exercise | 0.00 | 3,296 | 0 | 17,235 | 
| Colleran David | EVP, General Counsel, Corp Sec | Mar 10 '25 | Option Exercise | 0.00 | 5,465 | 0 | 39,590 | 
| Blanchard Cheryl R | President, CEO, Director | Mar 10 '25 | Option Exercise | 0.00 | 20,002 | 0 | 172,826 | 
        Apri su Yahoo
        |
        Apri su Google
            |
            Aperto in Finviz
        |
        Apri in MarketWatch
            |
            Aperto a EDGAR    
        |
        Aperto su Reuters
    
    
                Capitalizzazione:
                 
                  | 
                Volume (24 ore):
                 
            
         
                     
                             Scarica l'app Stockscreener
                    Scarica l'app Stockscreener